Finklestein
Jerome L. Finklestein, Maspeth, NY US
Patent application number | Description | Published |
---|---|---|
20090069760 | SYSTEMS AND METHODS FOR PROVIDING A DEBRIDING WOUND VACUUM - Thus, systems and methods for a debriding wound vacuum may include a sponge for application to a wound, a flexible sheet for covering and sealing the wound, and a bladder. The bladder may be in fluid communication with at least a portion of the sponge. The bladder preferably contains a debridement substance. A negative pressure device may form part of the system and may be used to apply negative pressure via a hollow tube to the sponge. The negative pressure device may be adapted to apply negative pressure to the sponge via the hollow tube in order form a seal between the flexible sheet and the wound. The systems may also include microelectronic mechanical valves for releasing the debridement substance from the bladder. | 03-12-2009 |
Seth Finklestein, Needham, MA US
Patent application number | Description | Published |
---|---|---|
20100322899 | METHODS OF IMPROVING CENTRAL NERVOUS SYSTEM FUNCTIONING - Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells. | 12-23-2010 |
Seth P. Finklestein, Needham, MA US
Patent application number | Description | Published |
---|---|---|
20090068156 | TREATMENT OF MUSCULAR DYSTROPHY WITH CORD BLOOD CELLS - The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion. | 03-12-2009 |
Seth Paul Finklestein, Durham, NC US
Patent application number | Description | Published |
---|---|---|
20120207749 | DOSING REGIMEN - The present invention relates to a dosing regimen for use in the treatment of stroke. More particularly, the invention relates to the administration of two doses of anti-MAG antibodies for the treatment of ischemic and/or haemorrhagic stroke. | 08-16-2012 |